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Abstract 
Coronavirus disease (COVID-19) caused by severe acute 
respiratory syndrome coronavirus 2 (SARS CoV-2) has 
turned out to be a formidable pandemic. Upcoming 
evidence from confirmed cases of COVID-19 suggests an 
anticipated incursion of patients with neurological 
manifestations in the weeks to come. An expression of the 
angiotensin-converting enzyme 2 (ACE 2), the cellular 
receptor for SARS-CoV-2 over the glial cells and neurons 
have made the brain a potential target. Neurotoxicity may 
occur as a result of direct, indirect and post-infectious 
complications. Attention to neurological deficits in COVID-
19 is fundamental to ensure appropriate, timely, beneficial 
management of the affected patients. Most common 
neurological manifestations seen include dizziness, 
headache, impaired consciousness, acute cerebrovascular 
disease, ataxia, and seizures. Anosmia and ageusia have 
recently been hinted as significant early symptoms in 
COVID-19. As cases with neurological deficits in COVID-19 
emerge, the overall prognosis is yet unknown. 
Keywords: Coronavirus, SARS-CoV-2, COVID-19, ACE 2, 
Neurotoxicity, Brain, Seizures. 
DOI: https://doi.org/10.5455/JPMA.20 
Introduction 
Neurological symptoms of coronavirus disease (COVID-
19) can be minimal at presentation but these can cause 
monumental damage as silent contagious sources. With 
the recent outbreak, there is a compelling need to 
understand the potential of the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) to cause 
neurological illness for proper diagnosis and therapeutic 
decision making. 
The SARS-CoV-2 particle resembles a medieval European 
royal crown hence the name. The viral particle is enclosed 
by an envelope, and protein spikes from its membrane 
surface are responsible for interaction with host cell 
receptor and resultant virulence and infectivity. 
Angiotensin-converting enzyme 2 (ACE 2) is the cellular 
receptor for the new SARS-CoV-2 present on the brain and 
glial tissue and thus this makes the central nervous 
system (CNS) a potential target.1 There may be direct 
infiltration of the CNS through the nasal epithelium and 
entrance into the olfactory pathway with the subsequent 
retrograde trans-synaptic spread. However, secondary 
neurologic manifestations of COVID-19 are thought to be 
the result of widespread dysregulation of homeostasis 
and cytokine production with pulmonary, renal, hepatic, 
and cardiovascular injury.2 
Neurological symptoms fall into three main categories: 
CNS, peripheral nervous symptoms (PNS) and skeletal 
muscular symptoms.3 These clinical features may be the 
presenting complaints or as more commonly seen arise 
during the more frequently seen respiratory and febrile 
illness. CNS manifestations most commonly seen include 
dizziness, headache, impaired consciousness, acute 
cerebrovascular disease, ataxia, and seizures. PNS 
manifestations included taste impairment, smell 
impairment and nerve pain. Skeletal muscular injury 
manifestations include myalgias and rhabdomyolysis3 
(Table-1). These are likely due to significantly elevated 
pro-inflammatory cytokines in the serum and subsequent 
downregulation of anti-inflammatory cytokines. Besides 
coronavirus specific antibodies have been shown to 
activate macrophages resulting in their migration into the 
CNS and ultimately cause demyelination.4 
The American Academy of Otolaryngology recently 
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Table-1: Neurological Clinical Abnormalities with coronavirus disease (COVID-19). 
 
1. Central Nervous system: 
   a. Dizziness 
   b. Headache 
   c. Impaired consciousness 
   d.A cute cerebrovascular disease 
   e. Ataxia 
   f. Seizures 
2. Peripheral Nervous System: 
   a. Anosmia 
   b. Ageusia 
   c. Neuralgia 
3. Skeletal Muscle: 
   a. Myalgia
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proposed that anosmia, hyposmia, and dysgeusia should 
be added to the list of COVID-19 screening symptoms and 
urged precautionary isolation for individuals with these 
symptoms, even in the absence of respiratory disease.5 
In the largest study to date on 214 patients from Wuhan, 
China, overall, 78 patients (36.4%) had neurologic 
manifestations. The mean age of these patients was 52.7 
years. Of these patients, 83 (38.8%) had at least 1 of the 
following underlying disorders: hypertension (51 
[23.8%]), diabetes (30 [14.0%]), cardiac or cerebrovascular 
disease (15 [7.0%]), and malignancy (13 [6.1%]).3 A total of 
126 patients (58.9%) had non-severe infection and 88 
patients (41.1%) had severe infection according to their 
respiratory status. Patients with severe infection were 
more likely to develop neurologic manifestations, 
especially acute cerebrovascular disease [5.7%]; 
conscious disturbance [14.8%] and skeletal muscle injury 
[19.3%].3 Another recent report of 99 COVID-19 patients 
in Wuhan also described neurological complications with 
confusion (9%) and headache (8%) being most commonly 
seen.6 Loss of smell and taste may precede respiratory 
symptoms and suggest early neurological involvement. 
Respiratory failure in the absence of severe lung 
involvement may suggest neurogenic respiratory failure.7 
Most neurologic manifestations occur early in the illness 
(median time, 1-2 days). Of 6 patients with acute 
cerebrovascular disease, 2 arrived at the emergency 
department owing to the sudden onset of hemiplegia but 
without any typical symptoms of fever, cough, anorexia, 
and diarrhoea of COVID-19. Their lung lesions were found 
by an emergent lung CT and were diagnosed as having 
COVID-19 by a positive SARS-CoV-2 nucleic acid detection 
in the later stage.3 
Isolated new case reports of meningitis/encephalitis,8 
haemorrhagic necrotizing encephalopathies,9 Guillain-
Barre syndrome,10 with COVID-19 are emerging every day 
from all around the world. However, the neuroinvasive 
nature of the human coronavirus and an association with 
demyelination including multiple sclerosis11 and acute 
disseminated encephalomyelitis has long been known.12 
Laboratory findings in patients with COVID -19 include 
high white blood cell counts, lower lymphocyte count, 
and increased C-reactive protein. Severe infection have 
corresponding higher D-dimer levels, increased lactate 
dehydrogenase, alanine aminotransferase, and aspartate 
aminotransferase levels, with elevated blood urea 
nitrogen, creatinine levels, and creatinine kinase (CPK) 
levels3 (Table-2). 
Directed neurological workup depending upon the 
clinical concern is required. A non-contrast CT Head to 
exclude stroke in patients with possible or confirmed 
COVID 19 should be reserved for times when actionable 
information is likely to be obtained, or when a significant 
change in the neurological examination is seen. A CT 
angiogram of the head and neck may be required in cases 
of subarachnoid hemorrhage. Additional studies 
including MRI, echocardiograms and doppler should be 
considered only if there is a high likelihood of changing 
management as contamination issues are present. All 
electroencephalogram (EEG) orders must be discussed 
with EEG service attending and cases of seizures or 
possibility of non-convulsive seizures (seen in up to 10% 
of critically-ill patients) should ideally be performed with 
disposable EEG leads. A cerebrospinal fluid (CSF) 
examination may be required at the discretion of the 
neurology consultant to exclude possible causes of 
impaired consciousness. A lumbar puncture to look for 
SARS-CoV-2 nucleic acid by using PCR is recommended in 
highly suspicious cases. 
An over-emphasis on the fact that nerve conduction 
studies and needle electromyography are usually within 
normal limits in the first 1-2 weeks of diseases of the 
muscle and nerves cannot be made. No unnecessary 
procedures should be performed as the machines may 
serve as fomites and this needs close consideration. 
Standard management of stroke with suspected COVID-
19 requires certain considerations. Patients needing 
tissue plasminogen activator (tPA) during the one-hour 
infusion may be monitored every 15 minutes by one 
member of the stroke team in the patient's room to 
conserve personal protective equipment (PPE) and limit 
the potential for accidental exposure. In cases of 
mechanical thrombectomy, groin checks can be done by 
team members entering for other reasons every 4 hours 
after the initial monitoring in the intervention radiology 
suite.  
Limiting exposure to potentially infected patients of 
medical personnel and possible tele-neurology 
Table-2: Laboratory findings in coronavirus disease (COVID-19). 
 
Non Severe Infection                                                     Severe Infections 
 
Dearanged white blood cell count                                  Increased D dimer 
Raised neutrophil count                                                     Raised Creatine kinase  
Lower lymphocyte count                                                   Increased Lactate dehydrogenase 
Low Platelet count                                                               Raised Alanine aminotransferase 
Increased C reactive protein                                              Raised Aspartate aminotransferase  
                                                                                                   Raised Blood Urea Nitrogen  
                                                                                                   Raised Creatinine
consultations when possible cannot be overstated. 
Antiepileptic drugs that do not cause liver or renal 
damage should be considered for control of seizures and 
valproate should also be avoided in acute headache at 
this time in the context of its known hepatotoxicity.  
Also, the putative role of ACE2 in the pathophysiology of 
COVID-19 has recently fueled concerns regarding the use 
of non- steroidal anti-inflammatory drugs (NSAIDs) such 
as ibuprofen, commonly used for headache. These are 
known to induce up-regulation of ACE2 and, in theory, 
may facilitate infection with COVID-19.13 
The role of high dose intravenous immunoglobulins (IVIg) 
in a recent case series of patients with COVID-19, all of 
whom were successfully treated at the early stage of 
clinical deterioration has been published with the 
resultant initiation of a randomized controlled trial.14 This 
may lead us to rethink the equal efficacy that has been 
long established when treating patients with muscle or 
nerve involvement with plasma exchange versus IVIg. 
Practicing neurologists amid these critical times have 
considerable unanswered queries in their minds 
especially in underdeveloped countries. Do isolated 
neurological symptoms warrant a COVID-19 testing there 
and then before being a silent contagious source? Do we 
take sufficient steps in educating our patients who are on 
long-term use of immunosuppressants for illnesses like 
myasthenia gravis, multiple sclerosis, and sarcoidosis, and 
are now at a higher risk for COVID -19? Do Asians have an 
additional risk for strokes in these times because of the 
high prevalence of intracranial atherosclerosis here? Do 
larger pharmaceuticals need to change direction in the 
development of newer drugs and emphasise more on 
antiviral agents considering that only a handful are 
available? Is the COVID-19 here to stay? Will it become just 
become another herpes, dengue, chikungunya infection-
causing neurological manifestations that we have been 
commonly seeing over the past several years? 
Conclusion 
A cross-disciplinary unified approach is required in this 
herculean endeavour by mankind to control this outbreak 
as it still unfolds. Is this just a cursory glimpse of more 
formidable events to be revealed in the future? Only time 
will tell. Healthcare providers should keep a close watch 
for isolated neurological symptoms at presentation when 
evaluating patients for COVID-19 to assure both early 
appropriate management and control of disease. 
Research for new antiviral agents and the development of 
a possible vaccine is paramount and the time for action is 
now. This is the only way to assure containment of this 
suffering of humanity and its continued existence.  
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